Skip to main content
. Author manuscript; available in PMC: 2009 Sep 24.
Published in final edited form as: Ann Rheum Dis. 2007 Aug 2;67(4):478–484. doi: 10.1136/ard.2007.074104

Figure 4.

Figure 4

Time course of ACR50 response according to treatment and GGC homozygous haplotype carrier status. A. Patients treated with ADA plus methotrexate (MTX); B. Patients treated with ADA plus any other disease-modifying antirheumatic drug (DMARD); C. Patients treated with ADA alone; other=other than GGC homozygous haplotype; W=week.